Skip to main content
 

Moderator: Azizi Seixas, PhD

Moderator: Azizi Seixas, PhD

Azizi Seixas, Ph.D. is an associate professor at The University of Miami Miller School of Medicine, in the Department of Psychiatry and Behavioral Sciences. He is Director of the Media and Innovation Lab and Associate Director for the Center for Translational Sleep and Circadian Sciences. Dr. Seixas’ research broadly focuses on two areas: 1) biological, behavioral, clinical, environmental, and psychosocial determinants of cardiovascular and cardiometabolic disease/conditions, mental health, and brain health (dementia and aging), and 2) developing adaptive, precise, and personalized behavioral interventions to improve health and well-being with the use of machine learning, translational artificial intelligence, and digital technology. His work has been widely supported by National Science Foundation (NSF) and National Institutes of Health (NIH) and currently serves as PI on a NLHBI Career Award and a NHLBI R01 project.

Dr. Seixas is recognized as one of the top 100 Inspiring Black Scientists in America by Cell Press. Dr. Seixas has over 150 high impact peer-reviewed publications, book chapters and conference presentations and his work appears in several media-outlets such as CBS, CNN, NBC, Associated Press, The Guardian, Huffington Post, and is the sleep expert for NBC Health News. He is currently the Chair for the American Academy of Sleep Medicine  (AASM) Sleep Medicine Disruptors Conference and Change Agents program, Vice Chair of the AASM Artificial Intelligence and Machine Learning sub-committee, the Director of Early Career Faculty Development for NYU Langone Health’s Department of Population Health, member of the American Heart Association’s Cardiac Rehab Advisory Group, ad hoc NIH reviewer for MESH Study Review Panel, and former Chair of AASM’s Young Investigator Research Forum.

More News

  • Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF

  • AHA Innovators’ Network Member Accurkardia receives FDA Breakthrough Device Designation on New Condition Area

  • Target: BP™ initiative helps more than 9M Americans with hypertension